Chugai opens a new U.S. R&D shop; UCB gets EU nod for epilepsy drug;

@FierceBiotech: TEDMED 2015: A brief history of CRISPR and what's next. Article | Follow @FierceBiotech

@JohnCFierce: To me, the FDA review of drisa reads like a letter to DMD parents. You don't want this drug. Please don't be angry.  | Follow @JohnCFierce

@DamianFierce: "Did you name me after the mayor of New York, dad?" "Yes, Kristaps, but he was just a basketball player then." | Follow @DamianFierce

> Japanese drugmaker Chugai Pharma opened a new U.S. hub in Berkeley Heights, NJ, an outpost focused on early-stage and translational research. More

> European regulators recommended approval of UCB's brivaracetam, a treatment for epilepsy the company plans to market as Briviact. Story

> Italian biotech Newron Pharmaceuticals raised $5.4 million in a private placement. Item

> Aptose Biosciences ($APTO) suspended dosing of the cancer drug APTO-253 in a Phase Ib trial over patient safety concerns, and the FDA has placed a clinical hold on the program. News

Medical Device News

@FierceMedDev: The top women in medical devices 2015. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: St. Jude earns FDA approval for recharge-free spinal cord stimulation system. Article | Follow @VarunSaxena2

@EmilyWFierce: Dx Digest: Invitae builds out cancer and epilepsy testing menus; Illumina gets in on autism research. More | Follow @EmilyWFierce

> Bard to buy Liberator for $181M to improve access to home care market. Article

> Cancer diagnostics company closes up shop after 6-year FTC investigation. More

> Philips launches smartphone plug-in ultrasound handheld with app in U.S. Story

Pharma News

@FiercePharma: Price controls loom for generic drugs in India next year. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Baxalta Singapore plant gets FDA OK to produce Advate. Report | Follow @EricPFierce

> Horizon drops hostile takeover attack on Depomed after legal ruling. Report

> Merck KGaA rolls out big plans for expansion in Africa. Story

> Dr. Reddy's strikes back at AstraZeneca in purple pill courtroom battle. Article

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.